U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H12Cl2N2O
Molecular Weight 271.142
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PBT-1033

SMILES

CN(C)CC1=NC2=C(O)C(Cl)=CC(Cl)=C2C=C1

InChI

InChIKey=YZPOQCQXOSEMAZ-UHFFFAOYSA-N
InChI=1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3

HIDE SMILES / InChI
PBT-1033, also known as PBT-2, is a neural protective agent potentially for the treatment of Alzheimer's disease and Huntington's Disease. PBT-1033 is a moderate-affinity 8-hydroxyquinoline transition metal-ligand that acts as a synthetic chaperone, re distributing copper, zinc, and iron from locations where they are abundant to subcellular locations where they might be deficient. Delivery of copper and zinc by PBT-1033 into the cytoplasm deactivates the kinase glycogen synthase kinase 3β and the phosphatase calcineurin, both potential targets for Huntington’s disease. In aged wild-type mice, PBT-1033 improves cognitive ability and markers of neuronal plasticity and function. In Alzheimer’s disease mouse models, PBT-1033 inhibits the accumulation of amyloid β, attenuates neuropathological effects of amyloid β, including amyloid-β-induced hyperphosphorylation of tau, and improves cognition. In a 12-week, phase 2a, randomized, double-blind, placebo-controlled trial in 78 individuals with mild Alzheimer’s dementia, PBT-1033 was safe and well tolerated and significantly reduced concentrations of amyloid β42 in CSF.

Approval Year

PubMed

PubMed

TitleDatePubMed
PBT2 inhibits glutamate-induced excitotoxicity in neurons through metal-mediated preconditioning.
2015 Sep

Sample Use Guides

once daily 250 mg
Route of Administration: Oral
Name Type Language
PBT-1033
Common Name English
5,7-DICHLORO-2-N,N-DIMETHYLAMINOMETHYLQUINOLIN-8-OL
Systematic Name English
PBT-2
Code English
8-QUINOLINOL, 5,7-DICHLORO-2-((DIMETHYLAMINO)METHYL)-
Systematic Name English
PB 1033
Code English
5,7-DICHLORO-2-(DIMETHYLAMINOMETHYL)QUINOLIN-8-OL
Systematic Name English
Code System Code Type Description
CAS
747408-78-2
Created by admin on Sat Dec 16 11:32:32 GMT 2023 , Edited by admin on Sat Dec 16 11:32:32 GMT 2023
PRIMARY
EPA CompTox
DTXSID701029571
Created by admin on Sat Dec 16 11:32:32 GMT 2023 , Edited by admin on Sat Dec 16 11:32:32 GMT 2023
PRIMARY
PUBCHEM
10016012
Created by admin on Sat Dec 16 11:32:32 GMT 2023 , Edited by admin on Sat Dec 16 11:32:32 GMT 2023
PRIMARY
DRUG BANK
DB05565
Created by admin on Sat Dec 16 11:32:32 GMT 2023 , Edited by admin on Sat Dec 16 11:32:32 GMT 2023
PRIMARY
EVMPD
SUB196791
Created by admin on Sat Dec 16 11:32:32 GMT 2023 , Edited by admin on Sat Dec 16 11:32:32 GMT 2023
PRIMARY
SMS_ID
100000182617
Created by admin on Sat Dec 16 11:32:32 GMT 2023 , Edited by admin on Sat Dec 16 11:32:32 GMT 2023
PRIMARY
WIKIPEDIA
PBT2
Created by admin on Sat Dec 16 11:32:32 GMT 2023 , Edited by admin on Sat Dec 16 11:32:32 GMT 2023
PRIMARY PBT2 is an experimental drug candidate. It is a second-generation 8-hydroxyquinoline analog intended to be a successor to clioquinol and a potential treatment of Alzheimer's disease.Clinical trials: PBT2 was the subject of phase II clinical trials for Alzheimer's disease and Huntington's disease. The results for Alzheimer's disease failed to meet its goals, and there is no evidence that PBT2 is of any benefit in Alzheimer's dementia. The drug also missed efficacy goals for Huntington's disease.
FDA UNII
Q7K6GJQ4O4
Created by admin on Sat Dec 16 11:32:32 GMT 2023 , Edited by admin on Sat Dec 16 11:32:32 GMT 2023
PRIMARY